The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| SLN | -59.38% | -52.9% | -13.96% | -63% |
| S&P | +16.9% | +95.99% | +14.39% | +104% |
Silence Therapeutics Plc engages in the discovery, delivery, and development of ribonucleic acid (RNA) therapeutics. It also develops medicines by harnessing the body's natural mechanism of RNA interference within its cells. The company was founded on November 18, 1994 and is headquartered in London, the United Kingdom.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.23M | -70.0% |
| Gross Profit | $0.03M | 101.2% |
| Gross Margin | 14.06% | 355.2% |
| Market Cap | $273.94M | -69.0% |
| Market Cap / Employee | $2.51M | 0.0% |
| Employees | 109 | 0.0% |
| Net Income | -$27.68M | -41.0% |
| EBITDA | -$20.36M | 11.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $41.74M | -69.8% |
| Accounts Receivable | $0.09M | -96.0% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $0.00M | -100.0% |
| Q3 2024 | YOY Change | |
|---|---|---|
| Return On Assets | -43.26% | 0.0% |
| Return On Invested Capital | -254.85% | 11.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$22.08M | -311.8% |
| Operating Free Cash Flow | -$22.03M | -317.5% |
| Metric | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 5.65 | 6.77 | 1.05 | 2.43 | -93.83% |
| Price to Sales | 21.94 | 28.54 | 39.24 | 41.59 | - |
| Price to Tangible Book Value | 6.04 | 7.38 | 1.14 | 2.67 | -96.45% |
| Enterprise Value to EBITDA | -30.44 | -23.43 | 0.13 | -7.85 | -94.69% |
| Return on Equity | -222.6% | -49.4% | -63.8% | -99.2% | - |
| Total Debt | $0.23M | $0.19M | $0.06M | $0.00M | - |
SLN earnings call for the period ending June 30, 2021.
SLN earnings call for the period ending December 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
